Eric Mennesson

Eric Mennesson is a Head of cell biology and biomarker services platform at Tebubio since January 2008. Eric is also a Project Manager overseeing projects in cell biology, bioassays, and biomarkers. With a PhD in cellular and molecular biology from Université d'Orléans, Eric previously worked as a Scientific Researcher at Pierre Fabre Group, where Eric validated membrane protein CD151 as a therapeutic target. Notably, Eric identified protein interaction partners of CD151 in various cancer cell lines, contributing to the development of therapeutic mAbs. Additionally, Eric has achieved the development of gene KD SilenciX cell lines during their tenure at Tebubio.